Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,188 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HNSCC Clear all
Completed Early Phase 1 Interventional Results available

Neoadjuvant Imiquimod Immunotherapy for Oral Cancer

NCT04883645
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma
Interventions
Imiquimod 5% Cream
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 5, 2026, 10:48 PM EDT
Withdrawn Not applicable Interventional

Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)

NCT06603155
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Time restricted eating (TRE)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 5, 2026, 10:48 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

NCT06544655
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 5, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

NCT00139243
View directory record Official record
Conditions
Squamous Cell Carcinoma, Carcinoma of Head and/or Neck
Interventions
Taxotere, Cisplatin, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Sep 5, 2026, 10:48 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

NCT04848116
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Nivolumab, HuMax-IL8
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 5, 2026, 10:48 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 5, 2026, 10:48 PM EDT
Recruiting No phase listed Observational

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

NCT04564989
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Head and Neck Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
3
States / cities
Rochester, Minnesota • Chapel Hill, North Carolina • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 5, 2026, 10:48 PM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis

NCT02402348
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Metformin
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 5, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer

NCT01932697
View directory record Official record
Conditions
Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions
Docetaxel, Hyperfractionation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 5, 2026, 10:48 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

NCT05653882
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Interventions
etakafusp alfa (AB248), pembrolizumab
Biological
Lead sponsor
Asher Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 5, 2026, 10:48 PM EDT
Withdrawn Phase 1 Interventional

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

NCT01332279
View directory record Official record
Conditions
Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
Interventions
everolimus, erlotinib hydrochloride, biopsy, laboratory biomarker analysis, immunohistochemistry staining method, polyacrylamide gel electrophoresis, pharmacological study, external beam radiation therapy, microarray analysis
Drug · Procedure · Other + 2 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 5, 2026, 10:48 PM EDT
Withdrawn No phase listed Observational

Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer

NCT05296135
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
OncoPrism-HNSCC™
Diagnostic Test
Lead sponsor
Cofactor Genomics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 5, 2026, 10:48 PM EDT
Completed Early Phase 1 Interventional

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

NCT03868020
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Interventions
Computed Tomography, Fluciclovine F18, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 5, 2026, 10:48 PM EDT
Not listed No phase listed Observational

Sexual Behavior in Head and Neck Cancer Patients

NCT00662662
View directory record Official record
Conditions
Oropharyngeal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 5, 2026, 10:48 PM EDT
Active, not recruiting Phase 2 Interventional

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Dostarlimab, Belrestotug, Nelistotug, Remzistotug
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
New Haven, Connecticut • Iowa City, Iowa • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 5, 2026, 10:48 PM EDT
Completed No phase listed Observational

DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx

NCT00897988
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 5, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sorafenib/Cetuximab in Head and Neck Cancer

NCT00815295
View directory record Official record
Conditions
Squamous Cell Cancer
Interventions
Sorafenib, Cetuximab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 5, 2026, 10:48 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Head and Neck Cancer

NCT00404339
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
Robert Ferris
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Sep 5, 2026, 10:48 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

NCT06727565
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional Results available

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

NCT00503776
View directory record Official record
Conditions
Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
Interventions
exercise intervention, amifostine trihydrate, therapeutic dietary intervention
Behavioral · Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 5, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional

BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00057850
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 5, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck

NCT03057613
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, IMRT 60-66Gy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 5, 2026, 10:48 PM EDT
Completed No phase listed Observational

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

NCT06771674
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
Pembrolizumab, Nivolumab
Drug
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 5, 2026, 10:48 PM EDT
Recruiting Not applicable Interventional

ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx

NCT06915038
View directory record Official record
Conditions
Squamous Cell Carcinoma of Oropharynx, HPV Positive Cancer, Throat Cancer, Tonsil Cancer
Interventions
NavDx, Adjuvant Radiation 30 Gray, Adjuvant Radiation 40 Gray
Diagnostic Test · Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 5, 2026, 10:48 PM EDT